Umar Farooq

16.3k total citations · 2 hit papers
150 papers, 2.6k citations indexed

About

Umar Farooq is a scholar working on Oncology, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Umar Farooq has authored 150 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 53 papers in Pathology and Forensic Medicine and 27 papers in Surgery. Recurrent topics in Umar Farooq's work include Lymphoma Diagnosis and Treatment (49 papers), CAR-T cell therapy research (33 papers) and Chronic Lymphocytic Leukemia Research (21 papers). Umar Farooq is often cited by papers focused on Lymphoma Diagnosis and Treatment (49 papers), CAR-T cell therapy research (33 papers) and Chronic Lymphocytic Leukemia Research (21 papers). Umar Farooq collaborates with scholars based in United States, Pakistan and Canada. Umar Farooq's co-authors include James R. Cerhan, Matthew J. Maurer, Brian K. Link, Sattva S. Neelapu, Lynn Navale, Michael Crump, Christian Gisselbrecht, John Kuruvilla, William Y. Go and Sami Boussetta and has published in prestigious journals such as Science, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Umar Farooq

136 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

2017 1.0k citations Michael Crump, Sattva S. Neelapu et al. Blood profile →
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma

2024 77 citations Umar Farooq et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Umar Farooq United States	20	1.4k	993	557	343	328	150	2.6k
Robert M. Dean United States	26	916 0.7×	497 0.5×	418 0.8×	102 0.3×	525 1.6×	173	2.4k
Massimo Bernardi Italy	30	1.1k 0.8×	284 0.3×	631 1.1×	194 0.6×	633 1.9×	127	3.2k
A. Dompmartin France	31	1.4k 1.0×	590 0.6×	415 0.7×	1.5k 4.4×	291 0.9×	176	4.3k
Nicole R. LeBoeuf United States	27	1.1k 0.8×	555 0.6×	356 0.6×	149 0.4×	578 1.8×	144	2.6k
Olivier Tournilhac France	36	1.5k 1.1×	1.9k 1.9×	584 1.0×	241 0.7×	1.6k 4.9×	180	4.8k
James H. Pringle United Kingdom	38	1.2k 0.9×	624 0.6×	1.8k 3.3×	258 0.8×	649 2.0×	97	4.0k
Ritambhra Nada India	24	373 0.3×	315 0.3×	343 0.6×	714 2.1×	230 0.7×	288	2.5k
M Harada Japan	35	818 0.6×	260 0.3×	641 1.2×	300 0.9×	941 2.9×	169	3.9k
Seok‐Goo Cho South Korea	32	1.2k 0.9×	682 0.7×	746 1.3×	435 1.3×	1.2k 3.8×	330	4.5k
Dong‐Tsamn Lin Taiwan	33	450 0.3×	183 0.2×	710 1.3×	271 0.8×	564 1.7×	210	3.4k

Countries citing papers authored by Umar Farooq

Since Specialization

Citations

This map shows the geographic impact of Umar Farooq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Umar Farooq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Umar Farooq more than expected).

Fields of papers citing papers by Umar Farooq

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Umar Farooq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Umar Farooq. The network helps show where Umar Farooq may publish in the future.

Co-authorship network of co-authors of Umar Farooq

This figure shows the co-authorship network connecting the top 25 collaborators of Umar Farooq. A scholar is included among the top collaborators of Umar Farooq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Umar Farooq. Umar Farooq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tun, Aung M., Yucai Wang, Seth Maliske, et al.. (2024). Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica. 109(7). 2186–2195. 4 indexed citations

Deng, Changchun, Paolo F. Caimi, Umar Farooq, et al.. (2024). Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood. 144(Supplement 1). 94–94. 1 indexed citations

Arora, Jyoti, Sabarish Ayyappan, Bruce A. Smith, et al.. (2024). T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC. Blood. 143(18). 1816–1824. 15 indexed citations

Mott, Sarah L., et al.. (2024). Clinical outcomes of patients receiving three versus four doses of methotrexate with concomitant antithymocyte globulin in match unrelated donor allogeneic stem cell transplant: A single‐center experience. SHILAP Revista de lepidopterología. 5(3). 578–583.

Tun, Aung M., Yucai Wang, Seth Maliske, et al.. (2024). Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy. Transplantation and Cellular Therapy. 30(10). 1001.e1–1001.e12. 1 indexed citations

Karimi, Yasmin, Catherine Thiéblemont, Hervé Ghesquières, et al.. (2024). Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7039–7039. 5 indexed citations

Bock, Allison M., Raphael Mwangi, Yucai Wang, et al.. (2024). Defining primary refractory large B-cell lymphoma. Blood Advances. 8(13). 3402–3415. 7 indexed citations

Farooq, Umar, et al.. (2023). Gender and CVD- Does It Really Matters?. Current Problems in Cardiology. 48(5). 101604–101604. 48 indexed citations

Mohsin, Mashkoor, et al.. (2023). Case Study: Using a Shared International Database to Document Veterinary Consumption of Antibiotics in Pakistan. Antibiotics. 12(2). 394–394. 2 indexed citations

10.

Ahmed, Sohail, et al.. (2023). The protective role of maternal genetic immunization on maternal‐fetal health and welfare. International Journal of Gynecology & Obstetrics. 163(3). 763–777. 3 indexed citations

11.

Bock, Allison M., Jennifer Gile, Melissa C. Larson, et al.. (2023). Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer Journal. 13(1). 169–169. 3 indexed citations

12.

Tun, Aung M., Arushi Khurana, Raphael Mwangi, et al.. (2022). Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Advances. 6(17). 5210–5221. 7 indexed citations

13.

Mwangi, Raphael, Rebecca L. King, Matthew J. Maurer, et al.. (2022). Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis. Blood Advances. 6(24). 6180–6186. 1 indexed citations

14.

Castellino, Alessia, Yucai Wang, Melissa C. Larson, et al.. (2021). Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances. 6(4). 1350–1360. 13 indexed citations

15.

Nadiminti, Kalyan, Mehrdad Hefazi, Yogesh Jethava, et al.. (2021). A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. Blood Cancer Journal. 11(11). 183–183. 2 indexed citations

16.

Wang, Yucai, Umar Farooq, Brian K. Link, et al.. (2018). Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. Blood. 132(Supplement 1). 454–454. 1 indexed citations

17.

Crump, Michael, Sattva S. Neelapu, Umar Farooq, et al.. (2017). Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 130(16). 1800–1808. 1042 indexed citations breakdown →

18.

Mott, Sarah L., et al.. (2017). Frequency and Outcome of Clinically Signficant Incidental Findings in Plasma Cell Dyscrasias Patients Undergoing Whole Body FDG PET-CT Scan. Blood. 130. 5376–5376.

19.

Hamadani, Mehdi, Abraham S. Kanate, Alyssa DiGilio, et al.. (2017). Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation. 23(5). 853–856. 22 indexed citations

20.

Sargent, Daniel J., Qian Shi, Sharlene Gill, et al.. (2014). Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study. Clinical Cancer Research. 20(16). 4361–4369. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact